BioSpace News Archive

Drug Development

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6

January 9, 2020
·
5 min read
Business

Cerner to Release Fourth Quarter 2019 Earnings Results February 4

On the call, Cerner will discuss its results and outlook and answer questions from the investment community.

January 9, 2020
·
1 min read
Deals

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan. 9, 2020

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 29,750 shares of Puma common stock to three new non-executive employees.

January 9, 2020
·
2 min read
Business

Rockwell Medical, Inc. Appoints Russell H. Ellison, MD, MSc, to Board of Directors

Dr. Ellison has held leadership positions in both emerging biotechnology and large pharmaceutical companies for more than four decades.

January 9, 2020
·
7 min read
Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi

Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of €18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi.

January 9, 2020
·
3 min read
Deals

Mesa Labs Declares Quarterly Dividend payable on March 16, 2020

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

January 9, 2020
·
2 min read
Business

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Product designed to provide safer, more immediate treatment option for patients

January 9, 2020
·
3 min read
AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise

Trial to assess AMO-02 in treatment of congenital myotonic dystrophy to begin patient enrollment in early 2020.

January 9, 2020
·
2 min read
Deals

Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases

Bioniz Therapeutics, Inc. announced the execution of an option agreement for acquisition by Almirall including its lead candidate, BNZ-1.

January 9, 2020
·
4 min read
Policy

JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

JenaValve Pericardial TAVR System is the First Transcatheter Device to Achieve Breakthrough Device Designation; Prioritizes Premarket Approval Development Path for Severe Aortic Regurgitation Indication

January 9, 2020
·
3 min read